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Abstract
Although continued use of antidepressants (AD) has been found to be associated
with a lower risk of suicide, AD discontinuation is reported repeatedly. The aim
of this case‐control study, thus, was to assess whether discontinuation to AD was
associated with an increased risk of suicide, according to different genders and
age groups. The Social and Health Information System of Friuli Venezia Giulia
Region, Italy, was used to collect data on suicides, diagnoses and AD use from
2005 to 2014. We selected, as cases, all suicides that had at least one prescription
of AD in the 730 days before death (N = 876), and we matched with regard to
age and sex each case with five controls from the general population. Conditional
logistic regression analyses were used to assess the association between suicide
and modifications of AD treatment. We found that 70% of suicides and controls
from the general population discontinued AD in the 2 years before the index date.
In two‐thirds of them, discontinuations were two or more. Discontinuation of AD,
however, did not represent a significant risk factor for suicide. More appropriate
care of depression, particularly by primary care physicians who widely prescribe
AD, should be fostered in order to prevent suicide. However, more research is
needed to assess to which extent AD discontinuation can affect suicidal risk.
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1 | INTRODUCTION
Suicide prevention is a public health priority, since suicide
accounts for 1%‐4% of global mortality.1 Depression has
been indicated as one of the main risk factors behind sui-
cide.2 A logical consequence for prevention of suicide,
thus, should be to identify and treat individuals with
depressive disorders through health interventions, which
include antidepressant medication.3 Although the efficacy
of antidepressants in major depressive disorders has been
demonstrated in several clinical trials,4 inappropriate use in
clinical practice has been reported.5 Antidepressant
discontinuation, for instance, has been reported repeat-
edly.6-12 Furthermore, several studies observed that depres-
sion often remains untreated in suicidal individuals.13-17
Conversely, observational studies from many countries
observed that suicide rates decreased in parallel to an
increase of antidepressant prescriptions.3,18 Moreover, stud-
ies at the individual patient level found that continued use
of antidepressants was associated with a lower risk of sui-
cide deaths.19-22 In our previous studies from Friuli Vene-
zia Giulia region, Italy, we found an inverse association
between continuous use of antidepressants and suicide
risk,23 as well as a decreasing trend of suicide risk, when







subjects were adherent to antidepressant medication.17,24
Nonetheless, a better focus on the effect of antidepressants
on suicide risk using qualitative parameters had been
claimed.17 In this regard, it appears important to assess
whether discontinuation to antidepressants can affect sui-
cide risk. Further, it is crucial to explore suicide risk pat-
terns according to the use of antidepressants in different
genders and age groups, since important differences in
antidepressant utilization have been observed in women
compared to men, as well in older age groups compared to
younger age groups.9,12,25-27
The aim of the present case‐control study was to assess
whether discontinuation to antidepressants is associated
with an increased risk of suicide, according to different
genders and age groups.
2 | MATERIAL AND METHODS
The study was conducted in accordance with the Basic &
Clinical Pharmacology & Toxicology policy for experimen-
tal and clinical studies.28
2.1 | Selection of cases and controls
The Regional Social and Health Information System
(SISSR) of the Friuli Venezia Giulia (FVG) Region, Italy,
was used to select cases and controls. A unique anonymous
key is used by SISSR for the data linkage of different
regional databases (the Death Register, the Hospital Dis-
charge Register and the Drug Prescription Register).17,24
All residents in the region who died by suicide from 1
January 2005 to 31 December 2014 were identified from
the Death Register using ICD‐9 codes E95* and E98* for
intentional self‐harm and events of undetermined intent. To
be selected as cases, subjects who committed suicide had
to receive at least one prescription for an antidepressant
during their last 730 days of life. Five controls from the
FVG general population were matched, using incidence
density sampling method,29 by gender and year of birth to
each case. Additionally, controls had to be alive at the date
of suicide of their corresponding case (index date) and had
to have been dispensed at least one antidepressant in the
730 days prior to the index date.
2.2 | In‐patient diagnoses
The main in‐patient diagnoses were identified from the
Hospital Discharge Register, in case suicides and controls
had been hospitalized during the 730 days prior to the index
date. As in our previous study,17 we only used diagnoses
recorded in the first position on the medical record on dis-
charge from public and private hospitals covered by the
Regional Health System. They were arranged into three
groups, according to ICD‐9 codes: affective disorders (codes
296, 300.4, 311); non‐affective psychiatric disorders (codes
290‐295, 297‐300.3, 300.5‐310, 312‐319); and somatic dis-
orders (codes 001‐289; 320‐629; 680‐759; 780‐799). Com-
plications from pregnancy, childbirth and the puerperium
(codes 630‐679); certain conditions originating in the perina-
tal period (codes 760‐779); injury and poisoning (codes 800‐
999) and external causes of injury and supplemental classifi-
cation (codes E and V) were not considered and conse-
quently excluded from further analyses.
2.3 | Antidepressant discontinuation and
other treatment modifications
All prescriptions for antidepressants filled in FVG during
the 730 days prior to the index date were included in the
study. Prescriptions are reimbursed by the National Health
System, if prescribed by a general practitioner (GP) or
other public physician. They cover more than 90% of all
antidepressant prescriptions in the region.14 In the present
study, retrieved prescriptions included the date, the number
of packages, the volume (expressed in defined daily doses,
DDD) and the antidepressant substance name according to
its ATC code.30
Four classes of antidepressants were then merged and
used in the study: tricyclic antidepressants (TCA; ATC
code N06AA), selective serotonin reuptake inhibitors
(SSRI; N06AB), serotonergic‐noradrenergic reuptake inhi-
bitors (SNRI; N06AX21, N06AX16) and “other” antide-
pressants (N06AX49, N06AX12, N06AX11, N06AF03,
N06AX03, N06AX18, N06AX05).
The total number of prescriptions and the dispensed vol-
ume of each antidepressant were analysed in order to
assess modifications of treatment, namely discontinuations,
combinations and switches.
Discontinuation of antidepressants was assessed by ana-
lysing each patient's dispensing time‐line applying two con-
ditions:
1. The total number of DDD supplied in each prescription
for an antidepressant class was not sufficient to cover
the time up to the next prescription;
2. A gap lower than 31 days, starting from the last day
covered by the DDDs supplied at the index prescription,
until the date of next prescription for an antidepressant,
was allowed.
A sensitivity analysis was performed to assess the effect
of changing the gap to define discontinuation, that is,
assessing 15, 45, 60 and 90 days.
Discontinuation was assessed for each antidepressant
class. Type of antidepressant discontinuation was further
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obtained, with regard to each class and to more than one
class (ie, discontinuation of SSRI plus SNRI or discontinu-
ation of SSRI plus TCA and so on).
Moreover, it was determined whether a subject was dis-
continuing antidepressants during the 90 days before the
index date.
We also assessed the number of other treatment modifi-
cations:
1. Switch of antidepressant, defined as the discontinuation
of an index antidepressant and the dispensing of a pre-
scription of another specific antidepressant. A gap up to
31 days, starting from the last day covered by the
DDDs supplied at the index prescription, until the date
of prescription for the new antidepressant, as well as an
overlap of the two drugs up to 31 days, was allowed.7
2. Combination of antidepressant prescriptions, defined as
the duration of prescription for the index antidepressant
overlapping the duration of prescription of a second
antidepressant for more than 31 days.7
Figure 1 summarizes the evaluation of discontinuations,
combinations and switches.
Finally, we assessed for each individual the duration
of treatment, calculated as the time elapsed from the
date of first to the date of last prescription for an
antidepressant.
2.4 | Antidepressant data processing
Algorithms developed for interval temporal reasoning in
artificial intelligence31,32 were used to process data for dis-
continuations, combinations and switches. Data were reor-
ganized for each patient as a sequence of intervals,
corresponding to the temporal duration of different pre-
scriptions, computed using DDD information available in
the dataset. We then inspected these temporal data and
extracted, for each patient, the presence and duration of
discontinuation events, filtering them for minimum length
(a parameter we varied for sensitivity analysis). We further
identified all events corresponding to a change in therapy,
distinguishing only different classes of drugs.
2.5 | Statistical analyses
Continuous variables were summarized using the median as
a measure of central tendency and the range as a measure of
dispersion, whereas dichotomous or categorical variables are
tabulated into contingency tables. For continuous variables
(ie, number of antidepressant prescriptions), Mann‐Whitney
test was used to test the differences between means. For cate-
gorical variables, the chi‐square statistic (χ2) was used to test
the differences between observed and expected frequencies.
Conditional logistic regression analysis was used to









Evaluation of  combinations:
Index date
730 d





















FIGURE 1 Schematic examples for
describing the evaluation of
discontinuations, switches and
combinations. Each bar represents the
number of DDDs supplied at each
prescription. AD, antidepressants; DDD,
defined daily doses; Other, “other”
antidepressants; SNRI, serotonergic
noradrenergic reuptake inhibitors; SSRI,
selective serotonin reuptake inhibitors;
TCA, tricyclic antidepressants
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suicide) and predictors (time from first antidepressant pre-
scription to index date, antidepressant discontinuation).
Crude and adjusted odds ratios (OR) and 95% confidence
intervals (95% C.I.) were estimated from the logistic regres-
sion coefficients and their respective standard errors. ORs
were adjusted for gender, age, hospital diagnoses, length of
treatment and antidepressant treatment modifications. A P‐
value (P) < 0.05 was set as the threshold for statistical signifi-
cance. Stratified analyses were performed according to male
and female gender and age groups (0‐59 and ≥60 years).
Descriptive and inferential analyses were conducted
using the statistical software Stata/SE (version 13.1).
3 | RESULTS
Three‐hundred thirty‐two women and 928 men committed
suicide in FVG during the years 2005‐2014, while indivi-
duals older than 60 years of age were 527 and younger were
733. The percentage of suicides treated with antidepressants
was more than 80% in women and in persons older than
60 years, while it was around 60% in men and in younger
persons.
3.1 | Prescriptions of antidepressants
Overall, the mean number of prescriptions filled in the 2 years
before the index day was 14.3 in cases (median = 10; range =
1‐138) and 10.6 in controls (median = 6; range = 1‐98;
Mann‐Whitney test (P) < 0.001).
As shown in Table 1, significant differences were found
when genders and age groups were compared with regard
to the mean number of prescriptions.
Selective serotonin reuptake inhibitors accounted for
more than 90% of the prescriptions in cases and in con-
trols, in all genders and age groups.
3.2 | Antidepressant discontinuation
Overall, 241 cases (27.5%) discontinued antidepressant
treatment once during the 2 years prior to death, and 388
cases (44.3%) discontinued treatment twice and more, while
controls were 938 (21.4%) and 2079 (47.5%), respectively
(χ2(P) < 0.001). SSRIs accounted for 75% of discontinua-
tions in both cases and controls.
The proportion of subjects who discontinued antidepres-
sants was higher among SSRI users, varying from 75% to
55%, with regard to cases and controls of different gender and
age groups. Lower proportions of discontinuations were found
in subjects prescribed other antidepressant classes (Table S1).
In the 90 days prior to suicide, 65 women (24.4%) and
145 men (23.8%) discontinued antidepressants (χ2(P) =
NS), while suicides aged 0‐59 years were 82 (19.9%) and
suicides aged 60 years and older were 128 (27.6%;
χ2(P) < 0.05). SSRI accounted for more than 90% of dis-
continuations, in all genders and age groups.
3.3 | Other antidepressant treatment
modifications
Almost half of female and male cases modified antidepres-
sant treatment during the 2 years prior to the index date,
while this proportion was greater in male controls than
female χ2(P) < 0.05). The older age group was more likely
to modify antidepressant treatment than the younger age
group in both cases and controls (χ2(P) < 0.001; Table 2).
3.4 | Psychiatric and somatic diagnoses
Among cases, 6% were diagnosed with affective disorders,
12% with non‐affective psychiatric disorders and 44% with
somatic disorders. Controls were 0.3%, 1.4% and 53%,
respectively.
TABLE 1 Numbers (N), mean, standard error, median and range of antidepressant prescriptions in suicides and controls during the 730 d


























Females 268 16.1 11 1‐138 1340 9.6 5 1‐71




Age group 0‐59 412 9.4 5 1‐60 2073 5.6 3 1‐67




AD, antidepressants; N, numbers.
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Number and proportions of diagnoses with regard to
genders and age groups are summarized in Table 2.
3.5 | Conditional regression analyses
As summarized in Table 2, in the adjusted analyses, dis-
continuation did not significantly affect suicide risk in all
genders and age groups.
No differences in suicide risk were observed when the
analysis was stratified per type of discontinuation (ie,
SSRI, SNRI, TCA, other antidepressants and more classes
of antidepressants; data not shown).
In crude and adjusted analyses, the risk of suicide was
significantly increased by treatment modifications in both
genders and age groups (ORs varying from 2.0 to 1.4 in
adjusted analyses; Table 2).
TABLE 2 Numbers (N), percentages (%), crude and adjusted odds ratio (OR) and 95% confidence intervals (95% C.I.) of suicide in
antidepressants users in the 730 d prior to index date, according to psychiatric and somatic in‐patient diagnoses, antidepressant treatment
modifications and discontinuations
Cases Controls Crude suicide risk
Adjusted suicide
riska
N % N % OR 95% C.I. OR 95% C.I.
Females
Affective disorders 32 11.9 4 0.3 52.4 16.0‐171.1 28.8 8.2‐101.1
Non‐affective disorders 49 18.3 22 1.6 13.0 7.6‐22.4 8.7 4.7‐16.2
Somatic disorders 122 45.5 683 51.0 0.8 0.6‐1.0 0.7 0.5‐0.9
Time from first to last AD prescription ≥270 d 202 75.4 868 64.8 1.8 1.3‐2.5 1.3 0.8‐2.1
Treatment modificationsb 134 50.0 454 34.0 2.1 1.6‐2.8 1.8 1.3‐2.6
Discontinuations 203 75.5 941 70.2 1.3 1.0‐1.8 1.0 0.6‐1.5
Males
Affective disorders 21 3.4 9 0.3 12.8 5.7‐28.9 5.8 2.4‐14.1
Non‐affective disorders 58 9.5 40 1.3 7.6 5.0‐11.5 6.5 4.2‐10.1
Somatic disorders 267 43.9 1638 54.0 0.5 0.5‐0.8 0.5 0.4‐0.7
Time from first to last AD prescription ≥270 d 416 68.4 1974 64.9 1.2 1.0‐1.4 1.0 0.7‐1.4
Treatment modificationsb 282 46.4 1164 38.3 1.5 1.2‐1.8 1.4 1.2‐1.8
Discontinuations 426 70.1 2076 68.3 1.1 0.9‐1.3 1.1 0.8‐1.4
Age group 0‐59
Affective disorders 34 8.2 6 0.3 33.4 13.1‐85.5 18.4 6.3‐53.2
Non‐affective disorders 71 17.2 23 1.1 19.9 11.7‐33.8 16.4 9.3‐29.0
Somatic disorders 135 32.8 856 41.3 0.7 0.5‐0.8 0.5 0.4‐0.7
Time from first to last AD prescription ≥270 d 232 56.3 967 46.6 1.5 1.3‐1.9 1.0 0.7‐1.5
Treatment modificationsb 144 34.9 420 20.3 2.2 1.7‐2.8 1.9 1.5‐2.6
Discontinuations 258 62.6 1157 55.8 1.4 1.1‐1.7 1.1 0.8‐1.6
Age group ≥60
Affective disorders 19 4.1 7 0.3 15.4 6.1‐38.6 8.1 3.0‐21.5
Non‐affective disorders 36 7.8 39 1.7 4.7 2.9‐7.4 3.3 2.0‐5.6
Somatic disorders 254 54.7 1465 63.5 0.7 0.5‐0.8 0.6 0.5‐0.8
Time from first to last AD prescription ≥270 d 386 83.2 1875 81.3 1.2 0.9‐1.5 1.0 0.7‐1.5
Treatment modificationsb 272 58.6 1198 51.9 1.3 1.1‐1.6 1.3 1.1‐1.7
Discontinuations 371 80.0 1860 80.6 1.0 0.7‐1.2 0.9 0.7‐1.3
Statistically significant ORs are highlighted in bold.
AD, antidepressant.




3.6 | Sensitivity analysis
As summarized in Figures 2 and 3, a longer treatment gap
to define discontinuation would increase the estimated pro-
portion of subjects remaining on antidepressant treatment
in both cases and controls. Nonetheless, this relation did
not change the association between discontinuation of
antidepressants and suicide risk, which was still found non‐
significant in all genders and age groups (data not shown).
4 | DISCUSSION
4.1 | Antidepressant prescriptions
Antidepressants were more dispensed to females and to
older subjects, consistent with international findings and
previous findings from the region.12,14,24,25,33 Moreover,
differences between genders and age groups were found
with regard to the mean number of prescriptions, with sui-
cides in the older age group having filled the greatest num-
ber. However, subjects older than 60 years were more
likely to discontinue antidepressant treatment compared to
younger subjects, in contrast to previous findings.7,9 An
explanation for this may be that elderly may have been dis-
pensed with lower doses of antidepressants and, conse-
quently, a lower number of DDDs, which might have
affected the discontinuation gaps.34
The antidepressant class most commonly dispensed was
SSRI, in line with international and Italian litera-
ture.6,10,22,27,35,36
4.2 | Antidepressant discontinuation and
suicide
In the present study, we demonstrated that 70% of suicides
and controls from the general population discontinued
antidepressant treatment in the 2 years before the index
date. In two‐thirds of them, the number of discontinuations
was two or more. Further, one in four suicides discontinued
antidepressants in the 90 days prior to death. Discontinua-
tion of antidepressants has been reported repeatedly, with
proportions varying from 20% to 75% according to the
study period considered, the definition of discontinuation
(ie, using treatment gaps or only treatment abandonment),
the type of subjects included (ie, patients with a depressive
disorder or general population) and the class of antidepres-
sants considered.6,8-11 Serna,10 for instance, observed that
75% of subjects in their cohort discontinued treatment after
11 months, consistently with our findings. An Italian
study,6 however, found that only 27.5% of antidepressant
users discontinued treatment during 1‐year follow‐up. We
found a proportion of discontinuations in controls from the
general population three times higher, compared to this pre-
vious study. Since most of prescriptions in FVG are filled
by general practitioners (GPs),17 we agree with Trifiro et
al6 that reasons for discontinuation may be a lower aware-
ness of GPs in following clinical practice guidelines, as
well as a higher tendency of filling inappropriate prescrip-
tions for vague symptoms. Interestingly, we also found that
about 40% of controls modified treatment during the study
period, which may reflect a general difficulty by GPs in
identifying a beneficial medication. Differently, the high
percentage of discontinuations and treatment modifications
found in suicides may be explained by the fact that many
of them may be resistant to antidepressants, as previously
observed.17 In support of this hypothesis, treatment modifi-
cations were an independent suicidal risk factor in both
genders and age groups.
Further, few studies analysed whether antidepressant


































AD treatment gap to define discontinuation (d)
Cases F Cases M Controls F Controls M
FIGURE 2 Proportions of male and female cases and controls
who did not discontinue antidepressant treatment during the 730 d



































AD treatment gap to define disconnuaon (d)
Cases 0-59 Cases ≥60 Controls 0-59 Controls ≥60
FIGURE 3 Proportions of cases and controls aged 0‐59 y and
60 y and older who did not discontinue antidepressant treatment
during the 730 d prior to the index date. Sensitivity analysis of
different gaps defining discontinuation of treatment
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from the United States found an increased rate of suicidal
behaviour after discontinuation of antidepressants.37 Simi-
larly, Valuck et al38 observed a 60% increase of suicide
attempts after antidepressant discontinuation. A Danish
study,15 however, did not find differences in suicide risk in
subjects aged 50 years and over who discontinued antide-
pressant treatment compared to those who continued treat-
ment. This was consistent with our results, which could not
identify discontinuation as a significant risk factor for sui-
cide in subjects of all genders and age groups.
In contrast to other studies,7,9,34 SSRIs accounted for
more than 70% of discontinuations. Treatment discontinua-
tion may be related to different factors, such as a lack of
effect or the onset of adverse effects, as well as patient
compliance, which can be related to psychological reasons
or interactions with doctors.21,37,39,40 Further, a Danish
study11 had observed that the more GPs prescribed antide-
pressants, the more they were discontinued. GPs are more
likely to prescribe SSRIs, due also to their safety in over-
dose compared to older antidepressants.6,17 This prescribing
pattern,11 thus, might occur also in case of patients at a
greater risk of suicidal behaviour.37 Conversely, this may
explain the lower discontinuation rate observed in the pre-
sent study among TCA users compared to other antidepres-
sant classes. Consistent to our study, however, Yerevanian
et al37 found no differences in suicidal behaviour risk when
comparing SSRI and TCA discontinuation.
4.3 | Strengths and limitations
The main strength of this study is that it used population‐level
data from real‐world subjects treated with antidepressants dur-
ing a 10‐year period. Further, several confounding factors
were taken into account, such as gender, age, hospital diag-
noses, length of treatment and antidepressant treatment modi-
fications. Selection bias was minimized, since the study was
based on register data of all suicides and matched controls
derived from the regional population.17,24 To our knowledge,
this is also the first study analysing types of discontinuation
within different antidepressant classes in suicides and controls,
as well as discontinuation of antidepressant as independent
risk factor for suicide in all genders and age groups.
A number of limitations, however, should be taken into
account. Firstly, the case‐control study design did not allow
to analyse to which extent subjects dispensed antidepres-
sants before the study period was started (ie, 730 days prior
to the index date). Secondly, only antidepressant prescrip-
tions issued by GPs and other public physicians were avail-
able from the health database, albeit we demonstrated that
this constitutes 90% of the prescriptions.14 Thirdly, actual
adherence to treatment could not be assessed, as seen in
the literature based on prescription registers.7,9,10,21,23,24
Fourthly, we had no information on the reasons for
discontinuation and treatment changes. Fifthly, our results
could have been influenced by the treatment gap used to
define discontinuation and the DDDs may not have been
representative of the actual doses given. However, our
additional sensitivity analysis, in which different lengths of
treatment gap were considered, did not change the associa-
tion between discontinuation of antidepressants and suicide
risk. In this regard, it is noteworthy that the number of
days without medication between fills had been demon-
strated to improve the ability to predict antidepressant per-
sistence.41 Sixthly, some discontinuations may have been
representing the conclusion of an adequate treatment for a
proper length of time, which is set between 9 and
12 months after recovery.42 Nonetheless, this seems to
have influenced minimally our results, since only a small
proportion of subjects were prescribed antidepressants for
more than 9 months without discontinuation. Further, no
differences in suicide risk were found in subjects discontin-
uing antidepressants, after adjusting for the duration of
treatment. Seventhly, the database provided only diagnoses
received at hospital and outpatient diagnoses were not
available. As a consequence, an overestimate of suicide
risk may have occurred, since inpatients are usually more
severely ill.17,24 On the other hand, an underestimate of
depression as an indication for antidepressant may also
have occurred.17 However, a previous database study found
that antidepressants are prescribed for depression in more
than half of the cases.43 Still, it cannot be excluded that
there is residual confounding‐by‐indication potentially lead-
ing to lack of association between discontinuation and sui-
cide. Finally, other limitations regarded the fact that we
could not adjust the analyses for other factors, such as
socio‐economic features, as well as we had no information
on suicide methods, like antidepressant poisoning.17,24
5 | CONCLUSIONS
Although we could not identify antidepressant discontinua-
tion as an independent suicidal risk factor, our finding of
three subjects out of four discontinuing treatment is of
major interest. An adequate antidepressants treatment, in
fact, is likely to be a crucial factor for preventing sui-
cide.15,17,37 In a number of studies, adherence to antide-
pressants was also associated with a decrease in suicide
rates.19-22 Further, the fact that other modifications of treat-
ment were positively associated with suicide in all genders
and age groups may indicate that more efforts are needed
to monitor antidepressants in individuals who are likely to
be treatment‐resistant. Since antidepressants are widely pre-
scribed by primary care physicians, our findings might sug-
gest that GPs should be more aware when antidepressants
are frequently combined or switched.
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Notwithstanding the limitations, this study adds evi-
dence that a more appropriate care of depression should be
fostered in the prevention of suicide. More research is
needed to assess to which extent antidepressant discontinu-
ation can affect suicidal risk.
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